Company Overview
Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
Professor Kataoka and Professor Yokota have codeveloped breakthrough technology enabling drug delivery across the blood-brain barrier (BBB) in close combination with nano-material engineering and neuroscience expertise, respectively.